Diagnostics developer T2 Biosystems files for a $69 million IPO

By
A A A

T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company claims that its technology platform will lead to an earlier detection of sepsis, which is the most expensive hospital-treated condition in the US with a 30% mortality rate. Combined with the detection of impaired hemostasis, T2 pegs its annual US addressable market at $3 billion. Primary backers include Goldman Sachs ( GS ), Polaris Partners and Flagship Ventures.

The Lexington, MA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol TTOO. T2 Biosystems initially filed confidentially on April 24, 2014. Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: GS , TTOO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

60%
100%

Most Active by Volume

57,375,820
  • $16.20 ▼ 0.80%
46,357,695
  • $102.13 ▲ 1.23%
39,856,106
  • $3.59 ▲ 0.84%
36,749,915
  • $19.21 ▲ 5.38%
35,094,671
  • $74.63 ▼ 1.75%
25,538,058
  • $48.06 ▼ 0.23%
24,241,250
  • $38.18 ▲ 1.03%
22,422,839
  • $11.20 ▲ 3.70%
As of 8/27/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com